BRIM closes a $45.8 million rights issue early to accelerate its pipeline of regenerative peptides

Taipei, Taiwan, 13th September 2023 / Sciad Newswire / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company focusing on developing regenerative peptides for ophthalmology and degenerative joint diseases, announced today that 22,500 shares have been issued at...

Related Keywords

Taiwan ,Taipei ,T Ai Pei ,Andrew Lin ,Wen Chyi Shyu ,Yi Chun Maria Chen ,Maria Patey Sophie Protheroe ,Tairx Inc ,Affinity Health Fund ,Biotechnology Inc ,Affinity Capital Inc ,Sciad Communications ,Sciad Newswire ,Pigment Epithelium Derived Factor ,Short Peptide ,Nuwa Healthcare ,Affinity Capital ,Affinity Health Fund One ,Health Fund Two ,Executive Officer ,Chun Maria Chen ,Dry Eye Disease ,Dry Eye ,Global Data ,